Published in Cancer Cells on March 01, 1991
Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol (1995) 10.61
Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat Biotechnol (2007) 3.54
Rous-Whipple Award Lecture. How tumors make bad blood vessels and stroma. Am J Pathol (2003) 1.95
Screening phage display libraries for organ-specific vascular immunotargeting in vivo. Proc Natl Acad Sci U S A (2005) 1.46
Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: a pathway to overcome cell barriers to drug and gene delivery. Proc Natl Acad Sci U S A (2002) 1.43
Peptidic tumor targeting agents: the road from phage display peptide selections to clinical applications. Curr Pharm Des (2010) 1.23
Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice. Int J Cancer (2008) 1.19
Epidermal growth factor receptor-targeted immunophotodiagnosis and photoimmunotherapy of oral precancer in vivo. Cancer Res (2001) 1.18
Tumour vasculature--a potential therapeutic target. Br J Cancer (1995) 1.14
Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci U S A (1993) 1.06
Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature. Int J Cancer (2009) 1.03
Near-infrared-resonant gold/gold sulfide nanoparticles as a photothermal cancer therapeutic agent. Small (2010) 1.03
Photo-targeted nanoparticles. Nano Lett (2010) 1.00
Imaging beyond the proteome. Chem Commun (Camb) (2012) 0.95
Immunotargeting and cloning of two CD34 variants exhibiting restricted expression in adult rat endothelia in vivo. Am J Physiol Lung Cell Mol Physiol (2009) 0.92
In vivo fluorescence imaging of the transport of charged chlorin e6 conjugates in a rat orthotopic prostate tumour. Br J Cancer (1999) 0.90
Incorporation of tumor vasculature targeting motifs into moloney murine leukemia virus env escort proteins enhances retrovirus binding and transduction of human endothelial cells. J Virol (2000) 0.88
Effect of tumour cell-conditioned medium on endothelial macromolecular permeability and its correlation with collagen. Br J Cancer (1996) 0.83
Cell and tissue distribution of synthetic oligonucleotides in healthy and tumor-bearing nude mice. An autoradiographic, immunohistological, and direct fluorescence microscopy study. Am J Pathol (1995) 0.82
Targeting and imaging signature caveolar molecules in lungs. Proc Am Thorac Soc (2009) 0.81
Antibody library-based tumor endothelial cells surface proteomic functional screen reveals migration-stimulating factor as an anti-angiogenic target. Mol Cell Proteomics (2008) 0.81
Reduced capacity of tumour blood vessels to produce endothelium-derived relaxing factor: significance for blood flow modification. Br J Cancer (1996) 0.80
Principles of antibody therapy. BMJ (1992) 0.80
Specific binding of TES-23 antibody to tumour vascular endothelium in mice, rats and human cancer tissue: a novel drug carrier for cancer targeting therapy. Br J Cancer (1999) 0.79
Thrombospondin modulates melanoma--platelet interactions and melanoma tumour cell growth in vivo. Br J Cancer (1995) 0.78
Angiogenesis and capillary maturation phenotypes associated with the Edpm3 locus on rat chromosome 3. Mamm Genome (2006) 0.78
Immunotherapy of hepatoma with a monoclonal antibody against murine endoglin. World J Gastroenterol (2007) 0.77
A fusion protein containing murine vascular endothelial growth factor and tissue factor induces thrombogenesis and suppression of tumor growth in a colon carcinoma model. J Zhejiang Univ Sci B (2008) 0.75
Molecular atherectomy for restenosis. Trends Cardiovasc Med (2011) 0.75
Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (1983) 15.43
Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol (1995) 10.61
Separation of caveolae from associated microdomains of GPI-anchored proteins. Science (1995) 5.25
The functional significance, distribution, and structure of LFA-1, LFA-2, and LFA-3: cell surface antigens associated with CTL-target interactions. J Immunol (1983) 4.17
Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev (1993) 3.96
Inducer T lymphocytes synthesize a factor that stimulates proliferation of cloned mast cells. Nature (1981) 3.71
Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol (1999) 3.42
Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med (1991) 3.15
Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol (1988) 3.06
Interleukin 3-dependent and -independent mast cells stimulated with IgE and antigen express multiple cytokines. J Exp Med (1989) 3.03
Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab Invest (2000) 2.92
Cutaneous basophil hypersensitivity. II. A light and electron microscopic description. J Exp Med (1970) 2.61
Neutrophils emigrate from venules by a transendothelial cell pathway in response to FMLP. J Exp Med (1998) 2.61
Mouse splenic and bone marrow cell populations that express high-affinity Fc epsilon receptors and produce interleukin 4 are highly enriched in basophils. Proc Natl Acad Sci U S A (1991) 2.41
Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim Biophys Acta (1989) 2.40
Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery. Am J Pathol (2001) 2.38
Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin. J Exp Med (1996) 2.26
Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS (1997) 2.24
Selective differentiation and proliferation of hematopoietic cells induced by recombinant human interleukins. Proc Natl Acad Sci U S A (1988) 2.22
Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing. Lab Invest (1987) 2.20
The vesiculo-vacuolar organelle (VVO): a distinct endothelial cell structure that provides a transcellular pathway for macromolecular extravasation. J Leukoc Biol (1996) 2.15
Induction of a fibrin-gel investment: an early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products. J Immunol (1979) 2.15
Regulation of extravascular coagulation by microvascular permeability. Science (1985) 2.11
Identification of a committed precursor for the mast cell lineage. Science (1996) 2.04
Why are tumour blood vessels abnormal and why is it important to know? Br J Cancer (2009) 2.00
Basophils and mast cells: morphologic insights into their biology, secretory patterns, and function. Prog Allergy (1984) 1.94
Mast cell clones: a model for the analysis of cellular maturation. J Cell Biol (1982) 1.91
Pathogenesis of ascites tumor growth: angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining. Cancer Res (1995) 1.79
Fibrin gel investment associated with line 1 and line 10 solid tumor growth, angiogenesis, and fibroplasia in guinea pigs. Role of cellular immunity, myofibroblasts, microvascular damage, and infarction in line 1 tumor regression. J Natl Cancer Inst (1979) 1.79
The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med (2001) 1.77
Rejection of first-set skin allografts in man. the microvasculature is the critical target of the immune response. J Exp Med (1979) 1.74
Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res (1993) 1.71
Morphology of delayed-type hypersensitivity reactions in man. II. Ultrastructural alterations affecting the microvasculature and the tissue mast cells. Lab Invest (1976) 1.70
Morphology of delayed type hypersensitivity reactions in man. I. Quantitative description of the inflammatory response. Lab Invest (1974) 1.68
Caveolae from luminal plasmalemma of rat lung endothelium: microdomains enriched in caveolin, Ca(2+)-ATPase, and inositol trisphosphate receptor. Proc Natl Acad Sci U S A (1995) 1.66
Fibroblast migration in fibrin gel matrices. Am J Pathol (1993) 1.64
Tumor shedding and coagulation. Science (1981) 1.64
Pathways of macromolecular tracer transport across venules and small veins. Structural basis for the hyperpermeability of tumor blood vessels. Lab Invest (1992) 1.57
Induction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts. J Clin Invest (1994) 1.57
Crohn's disease: transmission electron microscopic studies. I. Barrier function. Possible changes related to alterations of cell coat, mucous coat, epithelial cells, and Paneth cells. Hum Pathol (1980) 1.56
Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. Int Arch Allergy Immunol (1995) 1.55
Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation. Ann N Y Acad Sci (1992) 1.54
Measurement of ionized calcium in blood platelets with the photoprotein aequorin. Comparison with Quin 2. J Biol Chem (1985) 1.49
Ultrastructural identification of the mouse basophil. Blood (1982) 1.47
Development of large numbers of mast cells at sites of idiopathic chronic dermatitis in genetically mast cell-deficient WBB6F1-W/Wv mice. Blood (1987) 1.43
BK-related polyomavirus vasculopathy in a renal-transplant recipient. N Engl J Med (2001) 1.41
Ultrastructural localization of the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) receptor-2 (FLK-1, KDR) in normal mouse kidney and in the hyperpermeable vessels induced by VPF/VEGF-expressing tumors and adenoviral vectors. J Histochem Cytochem (2000) 1.41
Loss of cell surface material from peritoneal exudate cells associated with lymphocyte-mediated inhibition of macrophage migration from capillary tubes. Lab Invest (1972) 1.41
Crohn's disease: transmission electron microscopic studies. II. Immunologic inflammatory response. Alterations of mast cells, basophils, eosinophils, and the microvasculature. Hum Pathol (1980) 1.40
Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells. J Invest Dermatol (1995) 1.39
Pathways of macromolecular extravasation across microvascular endothelium in response to VPF/VEGF and other vasoactive mediators. Microcirculation (1999) 1.38
Cellular and vascular manifestations of cell-mediated immunity. Hum Pathol (1986) 1.37
Crohn's disease: transmission electron microscopic studies. III. Target tissues. Proliferation of and injury to smooth muscle and the autonomic nervous system. Hum Pathol (1980) 1.36
Bullous pemphigoid, an ultrastructural study of the inflammatory response: eosinophil, basophil and mast cell granule changes in multiple biopsies from one patient. J Invest Dermatol (1982) 1.35
Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metastasis Rev (1983) 1.34
Lipid bodies: cytoplasmic organelles important to arachidonate metabolism in macrophages and mast cells. J Immunol (1983) 1.33
Antigen-induced IgE-mediated degranulation of human basophils. Lab Invest (1980) 1.32
Eosinophil lipid bodies: specific, inducible intracellular sites for enhanced eicosanoid formation. J Exp Med (1997) 1.32
Development of human mast cells from umbilical cord blood cells by recombinant human and murine c-kit ligand. Proc Natl Acad Sci U S A (1993) 1.30
Co-compartmentalization of MAP kinases and cytosolic phospholipase A2 at cytoplasmic arachidonate-rich lipid bodies. Am J Pathol (1998) 1.30
Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. Cancer Res (1983) 1.29
Caveolae and vesiculo-vacuolar organelles in bovine capillary endothelial cells cultured with VPF/VEGF on floating Matrigel-collagen gels. J Histochem Cytochem (1999) 1.27
Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med (1996) 1.27
Prey specialization may influence patterns of gene flow in wolves of the Canadian Northwest. Mol Ecol (2001) 1.23
Gastrointestinal autonomic nerve (GAN) tumor. Ultrastructural evidence for a newly recognized entity. Arch Pathol Lab Med (1986) 1.23
Human eosinophils can express the cytokines tumor necrosis factor-alpha and macrophage inflammatory protein-1 alpha. J Clin Invest (1993) 1.23
Hyperosmolar triggering of histamine release from human basophils. J Clin Invest (1981) 1.21
Human breast carcinoma: fibrin deposits and desmoplasia. Inflammatory cell type and distribution. Microvasculature and infarction. J Natl Cancer Inst (1981) 1.20
Ultrastructural evidence for release of major basic protein-containing crystalline cores of eosinophil granules in vivo: cytotoxic potential in Crohn's disease. J Immunol (1980) 1.20
Degranulation of basophilic leukocytes in allergic contact dermatitis reactions in man. J Immunol (1976) 1.18
Immunologic rejection of diethylnitrosamine-induced hepatomas in strain 2 guinea pigs: participation of basophilic leukocytes and macrophage aggregates. J Exp Med (1973) 1.18
Leaky vessels, fibrin deposition, and fibrosis: a sequence of events common to solid tumors and to many other types of disease. Am Rev Respir Dis (1989) 1.17
Different pathways of macromolecule extravasation from hyperpermeable tumor vessels. Microvasc Res (2000) 1.16
Basophil and mast cell degranulation: ultrastructural analysis of mechanisms of mediator release. Fed Proc (1983) 1.15
VEGF-A induces angiogenesis, arteriogenesis, lymphangiogenesis, and vascular malformations. Cold Spring Harb Symp Quant Biol (2002) 1.15
Reinterpretation of endothelial cell gaps induced by vasoactive mediators in guinea-pig, mouse and rat: many are transcellular pores. J Physiol (1997) 1.14
Microwave energy fixation for electron microscopy. Am J Pathol (1985) 1.14
Ultrastructural immunogold localization of tumor necrosis factor-alpha to the matrix compartment of eosinophil secondary granules in patients with idiopathic hypereosinophilic syndrome. J Histochem Cytochem (1993) 1.14
Cytoplasmic lipid bodies of human eosinophils. Subcellular isolation and analysis of arachidonate incorporation. Am J Pathol (1991) 1.13
Anaphylactic degranulation of guinea pig basophilic leukocytes. I. Fusion of granule membranes and cytoplasmic vesicles formation and resolution of degranulation sacs. Lab Invest (1981) 1.13
Development of human mast cells in vitro. Proc Natl Acad Sci U S A (1989) 1.13
Historical and ecological determinants of genetic structure in arctic canids. Mol Ecol (2007) 1.13